# The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism

> **NCT02111473** · PHASE4 · COMPLETED · sponsor: **Gulhane School of Medicine** · enrollment: 49 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** Testosterone

## Key facts

- **NCT ID:** NCT02111473
- **Lead sponsor:** Gulhane School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-05
- **Final completion:** 2014-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111473, "The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02111473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*